Abstract
Parkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods.